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OBJECTIVES The purpose of this study was to evaluate a potential correlation between apoptotic rate (AR),
post-infarction left ventricular (LV) remodeling, and clinical characteristics in subjects who
died late (10 days) after an acute myocardial infarction (AMI) with evidence of persistent
occlusion of the infarct-related artery at autopsy.
BACKGROUND Apoptosis contributes to myocardiocyte loss in cardiac disease and may have a pathophysi-
ologic role in post-infarction LV remodeling.
METHODS The AR was calculated at the site of infarction and in remote unaffected LV regions, using
co-localization of in situ end labeling for deoxyribonucleic acid fragmentation and immuno-
histochemistry for caspase-3, in 14 subjects who died within two months after AMI.
Correlation between AR and clinical characteristics such as age, site of AMI, transmural
extension, multivessel coronary disease, and signs and/or symptoms of heart failure (HF), at
the time of initial hospitalization for AMI or subsequently before death, was assessed using
non-parametric statistical tests. Parameters of LV remodeling including diameters, free wall
thickness, diameter-to-wall-thickness ratio, and mass were measured at gross examination at
autopsy. Values are expressed as median (interquartile range).
RESULTS Among clinical variables, early symptomatic post-infarction HF (9 cases, 64%) was associated
with nearly fourfold increased AR at the site of infarction (26.2% [24.5% to 28.8%] vs. 6.4%
[1.9% to 13.3%], p  0.001). Moreover, AR both at the site of infarction and in unaffected
regions was significantly correlated with parameters of progressive LV remodeling (p 0.05).
CONCLUSIONS Our data show that in patients dying 10 days after AMI, myocardial apoptosis is strongly
associated with and may be a major determinant of unfavorable LV remodeling and early
symptomatic post-infarction HF. (J Am Coll Cardiol 2003;41:753–60) © 2003 by the
American College of Cardiology Foundation
Unfavorable left ventricular (LV) remodeling (progressive
chamber dilation, wall thinning, and systolic/diastolic dys-
function) often complicates acute myocardial infarction
(AMI). This process involves cellular and molecular mech-
anisms beginning days after AMI and persisting for weeks
and months after the initial insult, both at the site of
infarction and in the surviving unaffected areas, occurring in
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a necrosis-independent manner (1–4). Three different
phases may be recognized in chronic post-infarction remod-
eling: an early phase of compensatory concentric hypertro-
phy, a subsequent phase of early dilation leading to decom-
pensated eccentric hypertrophy, and the end stage of
dilation with progressive wall thinning (3). Left ventricular
remodeling is associated with unfavorable hemodynamic
performance and adverse outcome during the long-term
follow-up, including symptomatic heart failure (HF), death
due to pump failure, and sudden cardiac death (1,2).
Myocardial apoptosis represents a potential pathophysio-
logic mechanism in HF progression (5,6). It is responsible
for myocardiocyte loss in the acute phases of AMI (7,8), in
the post-infarction period (9–11), and in end-stage HF
(12–15). Of note, in a selected cohort of subjects with recent
AMI, Baldi et al. (9) have found a significant correlation
between LV diameters at autopsy and apoptotic rates (AR)
in infarct regions, but not with AR in the remote areas.
Conversely, Palojoki et al. (10) have shown a significant
correlation between end-diastolic LV diameters and AR
in remote unaffected LV regions (and not in border zones)
in rats with AMI. Nonetheless, the causal role of apoptosis
in these clinical entities has not been completely established
yet, and little is known about the clinical and pathologic
meaning of apoptosis and a possible link between apoptosis,
unfavorable LV remodeling, and clinical presentation.
The goal of this study was to evaluate the potential
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correlation between AR at the time of death (both at the site
of infarction and in unaffected LV areas), clinical charac-
teristics of the subjects in the days preceding death (includ-
ing the occurrence of signs or symptoms of HF), and
macroscopic signs of LV remodeling in subjects dying late
(10 to 62 days) after AMI, all with persistent occlusion of
the infarct-related artery (IRA) occlusion (as IRA status
may itself influence AR) (16).
METHODS
We selected, at routine postmortem examination, 14 sub-
jects according to the following inclusion criteria: 1) death
due to nontraumatic cause, occurring 10 to 62 days after an
AMI; 2) persistent occlusion of the IRA documented at
postmortem examination; and 3) no clinical or pathologic
evidence of re-infarction. We collected data on initial
hospitalization for AMI in all cases. Site of infarction, IRA,
initial treatment (including fibrinolytic treatment for ST-
segment elevation AMI), and past medical history were
obtained from clinical charts. Clinical and laboratory data
regarding the days preceding death were available in all
cases. Re-infarction was excluded on the basis of clinical,
laboratory, and pathology data. Patients were considered to
be suffering from symptomatic HF if one or more of the
following signs, symptoms, or clinical characteristics had
been present in the days before death: dyspnea at rest (not
due to concomitant pulmonary or musculoskeletal disor-
ders) associated with jugular venous distension, third heart
sound and/or pulmonary rales, peripheral edema, elevated
pulmonary wedge pressure and/or central venous pressure,
reduced cardiac output, need of intravenous inotropic sup-
port and significant (4.5 kg) decrease in weight after
diuretic use (Stages C or D and New York Heart Associa-
tion functional class IV according to American College of
Cardiology/American Heart Association guidelines for the
evaluation and management of HF [17]). Treatment by
insulin or oral antidiabetic agents was used to define
diabetics.
Pathology. Gross examination of the hearts was performed
to measure various LV parameters, to define the infarcted
area, and to confirm total IRA occlusion. Cardiac diameters
were calculated at the atrioventricular section, and LV free
wall thickness was measured at the median third of the
unaffected free wall (usually the posterior wall). Infarcts
were defined as large infarcts if an area of transmural
necrosis involving more than one LV wall (approximately
30% of the circumference) was found at pathology. Left
ventricular hypertrophy was defined as LV wall thickness
15 mm in unaffected LV regions. A transverse diameter-
to-free wall thickness 9 was used to define LV dilation.
The combination of hypertrophy and dilation was defined as
eccentric hypertrophy. Pulmonary, liver, and/or renal con-
gestion and signs of renal and/or intestinal hypoperfusion
were considered pathologic evidence of HF as indirect signs
of chronic congestive state and circulatory failure (4,18).
Tissue specimens were obtained at sites of infarction (Fig.
1A) and in unaffected regions of the LV remote from the
infarcted area. Specimens were fixed in 10% paraformalde-
hyde. In situ end labeling of deoxyribonucleic acid (DNA)
fragmentation terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick end labeling
(TUNEL) was performed using the Apoptag kit (Oncor,
Gaithersburg, Maryland), according to the supplier’s in-
structions (Fig. 1B). For immunohistochemistry, the sec-
tions already treated for the TUNEL assay were heated and
then incubated with antibodies against muscle actin (mouse
monoclonal anti-human actin HHF35 from Dako, Carpin-
teria, California; dilution 1:50) and caspase-3 (rabbit poly-
clonal anti-human caspase-3 from Upstate Biotechnology,
Lake Placid, New York; dilution 1:100) and visualized by
the streptavidin-biotin system (Dako), using either
3-amino-9-ethylcarbazide (AEC) or diaminobenzidine as
the final chromogen (Figs. 1C and 1D). Myocardiocytes
were defined as apoptotic if co-localization of markers of
DNA fragmentation (TUNEL) and caspase-3 was evident
(Fig. 1D), according to the fact that high immunohisto-
chemical expression of caspase-3 detected with the antibody
used in this study is present in myocardiocytes undergoing
apoptosis, co-localizes with TUNEL-positive myocardio-
cytes, and corresponds mostly to increased expression of its
activated form (9,19,20). The AR was expressed as the ratio
of the number of myocardiocytes co-expressing TUNEL
and caspase-3 positivity on nucleated cells per field (250).
Muscle actin-negative cells as well as myocardiocytes co-
expressing TUNEL positivity and specific staining for
markers of DNA synthesis (proliferating cell nuclear anti-
gen [PCNA]) (using mouse monoclonal anti-human
PCNA PC10 antibody from Dako, dilution 1:100) and/or
markers of transcription activity (ribonucleic acid splicing
factor SC-35) (using mouse monoclonal anti SC-35 from
Sigma, Milan, Italy; dilution 1:200) were not included in
the cell count. TUNEL-negative/caspase-3-positive cells,
although likely to be cells committed to apoptosis, were not
considered to be apoptotic because caspase-3 activation may
represent a reversible step in the apoptotic cascade (6).
Suitable negative and positive controls for TUNEL and
caspase-3 were performed, as defined elsewhere (9). Briefly,
controls for TUNEL were performed as indicated by the
Abbreviations and Acronyms
AEC  3-amino-9-ethylcarbazide
AMI  acute myocardial infarction
AR  apoptotic rate
DNA  deoxyribonucleic acid
HF  heart failure
IRA  infarct-related artery
LV  left ventricle/ventricular
PCNA  proliferating cell nuclear antigen
TUNEL  terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick end
labeling
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supplier (using a normal female rodent mammary gland 3 to
5 days after weaning of rat pups for positive control and
sham staining leaving out active terminal deoxynucleotidyl
transferase but including proteinase K digestion to control
for nonspecific incorporation of nucleotides or for nonspe-
cific binding of enzyme-conjugate). A human lymph node
was used as a control for activated caspase-3 (strong immu-
noreactivity was evident in the apoptotic-prone germinal
center B-lymphocytes of the lymph node and not in the
mantle zone). Moreover, negative controls indicating the
non-interference of TUNEL and secondary antibodies were
performed by leaving out the primary antibodies (actin,
caspase-3, PCNA and SC-35 respectively).
Statistical analysis. For statistical analysis, the software
SPSS 10.0 for Windows (SPSS Inc., Chicago, Illinois) was
used. Quantitative results were expressed as median (inter-
quartile range). Nonparametric tests for non-paired data
were used to compare AR among different subjects, the
Mann-Whitney U test was used when two groups were
compared, and the Kruskal-Wallis test was used when more
than two groups were compared. Bonferroni’s correction
was applied to the Mann-Whitney U test when compari-
sons between multiple groups were performed. Correlation
between continuous variables was calculated with the Spear-
man correlation test. Discrete variables were compared by
logistic regression analysis. For variables associated with
statistical significance or borderline significance (p  0.10),
multivariable analysis was performed using a generalized
linear model following a multiple linear regression model
(using the default identity link function available on SPSS
10.0).
Table 1. Clinical and Demographic Characteristics of
the Patients
Number of patients 14
Age (median, yrs) 74
Interquartile range (69–79)
Gender (males, %) 11 (79%)
Clinical characteristics (%)
Anterior AMI 7 (50%)
Transmural AMI 12 (86%)
Large AMI 10 (71%)
Fibrinolytic treatment at time of initial AMI 4 (29%)
Persistent IRA occlusion 14 (100%)
Multivessel coronary disease 8 (57%)
Previous remote AMI (6 months earlier) 7 (50%)
Symptomatic HF 9 (64%)
Diabetes 1 (7%)
Time from AMI to death (median, days) 16
Interquartile range (12–34)
AMI acute myocardial infarction; HF heart failure; IRA infarct-related artery.
Figure 1. Characterization of apoptotic myocardiocytes. (A) Hematoxylin/van Gieson stain. Site of recent infarction: reparative fibrosis, newly sprouted
vessels, and granulation tissue (original magnification 500). (B) In situ end labeling of deoxyribonucleic acid (TUNEL) staining. Region of the left
ventricle at the site of infarction: TUNEL-positive nuclei (brown) are evident (original magnification 500; 3-amino-9-ethylcarbazide [AEC], lightly
counterstained with hematoxylin). (C) Double staining: nuclear staining for TUNEL and cytoplasmic staining for muscle actin. TUNEL-positive cells
(brown nuclear staining) co-express cytoplasmic muscle actin (original magnification 600; AEC, lightly counterstained with hematoxylin). (D) Double
staining: nuclear staining for TUNEL and cytoplasmic staining for caspase-3 (original magnification600; AEC, lightly counterstained with hematoxylin).
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RESULTS
Clinical data. Clinical characteristics of the patients are
shown in Table 1. In particular, median time to death post
AMI was 16 days. All patients had non-cardiac comorbidi-
ties at the time of death, which variably contributed to the
outcome (i.e., upper and lower gastrointestinal bleeding,
severe anemia, pulmonary infective infiltrates, stroke).
Three patients (21%) died during the initial hospital admis-
sion (at day 10); the others were discharged from the
hospital and subsequently readmitted before death. Seven
patients had an anterior AMI, and four received fibrinolysis
at the time of initial AMI. Nine patients (64%) had a
diagnosis of HF at the time of initial hospitalization for
AMI or subsequently before death, and five patients died
late after AMI without clinical evidence of HF. None of the
subjects had clinical or pathologic evidence of reinfarction
(Table 1).
Myocardial apoptosis and clinical variables. Among all
the available clinical variables shown in Table 1, symptom-
atic HF, fibrinolytic treatment, and history of previous
additional remote AMI were associated at univariate anal-
ysis with increased AR at the site of infarction. In particular,
subjects who experienced early occurrence of HF (9 cases)
had nearly fourfold increased AR versus the others (26.2%
[24.5% to 28.8%] vs. 6.4% [1.9% to 13.3%], p  0.001)
(Fig. 2). Fibrinolysis at the time of AMI (4 cases) and a
history of previous remote AMI (6 months earlier than
the more recent AMI; 7 subjects) were associated with a
nonsignificant trend toward higher AR (28.8% [20.5% to
32.8%] vs. 19.4% [5.6% to 26.0%], p  0.054 and 28.4%
[17.9% to 29.1%] vs. 14.6% [3.2% to 25.9%], p  0.073 for
fibrinolysis and previous remote AMI, respectively). At
multivariable analysis including these three parameters,
however, only HF remained significantly associated with
increased apoptosis (p  0.001), whereas effects of fibrino-
lytic treatment were lost (p  0.956) as well as history of
previous remote AMI (p  0.476).
When compared with the others, subjects with signs or
symptoms due to HF before death had, as expected, greater
LV transverse diameter (137 vs. 120 mm, p  0.012),
longitudinal diameter (110 vs. 100 mm, p  0.029),
transverse diameter-to-LV free wall thickness (10.0 vs. 8.0,
p  0.029), smaller LV free wall thickness (12 vs. 15 mm,
p  0.08), and greater cardiac mass (530 vs. 460 g, p 
0.029) at autopsy. Moreover, they were less likely to have
concentric compensatory hypertrophy (0% vs. 60%, p 
0.027), and more frequently they had indirect signs of
systemic congestion and/or hypoperfusion compatible with
the effects of a failing circulation assessed at pathology (80%
vs. 40%, p  0.25). Interestingly, considering the subjects
who met the clinical and/or pathologic criteria to define
HF, they (11 cases) had a significantly higher AR versus the
others, both at the site of infarction (25.9% [17.9% to
28.6%] vs. 6.4% [0.5% to 12.0%], p  0.022) and in remote
regions (0.7% [0.7% to 0.9%] vs. 0.3% [0.3 to 0.4], p 
0.022).
Apoptosis and cardiac remodeling. Analysis of correlation
between apoptosis and macroscopic signs of LV remodeling
revealed a statistically significant link between AR at both
sites (infarction and remote unaffected site) and macro-
scopic signs of cardiac remodeling (LV transverse and
longitudinal diameters, free wall thickness, diameter-to-wall
thickness ratio, and mass) (Table 2, Fig. 3).
Left ventricular dilation was found in 10 cases (71%), and
it was associated with significantly higher AR at the site of
infarction (26.0% [22.6% to 28.7%] vs. 7.6% [1.2% to
Figure 2. Myocardial apoptosis in subjects with early symptomatic post-
infarction heart failure. Apoptotic rate at the site of the infarction was
increased nearly fourfold in subjects with symptomatic heart failure at the
time of initial hospitalization for acute myocardial infarction or subse-
quently before death versus the remaining subjects (26.2% [24.5% to
28.8%] vs. 6.4% [1.9% to 13.3%], p  0.001). Column height  median
value; vertical bar  interquartile range.
Table 2. Gross Anatomy Characteristics of the Hearts and Correlation With Apoptotic Rates at
Site of Infarction and in Unaffected LV Sites
Median
[Interquartile Range]
Infarction Site Remote Site
r p r p
Cardiac diameters (mm)
Transverse 129 [122–139] 0.72 0.004* 0.19 0.52
Longitudinal 108 [102–115] 0.66 0.011* 0.54 0.047*
LV wall thickness (mm) 14 [11–15] 0.52 0.050* 0.72 0.004*
Diameter-to-thickness ratio 9.5 [8.8–12.2] 0.63 0.015* 0.62 0.017*
Cardiac weight (g) 485 [458–578] 0.48 0.08 0.52 0.050*
* p  0.05.
LV  left ventricular.
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Figure 3. Correlations between macroscopic signs of post-infarction left ventricular (LV) remodeling and apoptotic rate (AR) at the site of acute myocardial infarction and in remote unaffected LV regions.
Correlation between AR at the site of infarction and LV longitudinal (A) and transverse (B) diameter, free wall thickness (C), transverse diameter-to-free wall thickness (D), and cardiac weight (E). Correlation
between AR in remote regions and the same LV macroscopic parameters (F to L), respectively. Black and white dots represent subjects with (filled squares) and without (empty squares) early symptomatic
post-infarction heart failure, respectively.
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14.0%], p  0.008). Six subjects (43%) had signs of LV
hypertrophy. The AR in hearts with LV hypertrophy was
significantly reduced in the surviving unaffected areas (0.4%
[0.3% to 0.7%] vs. 0.9% [0.7% to 1.0%], p  0.029). The
combined effect of LV dilation and hypertrophy is shown in
Figure 4. The AR in both infarct and remote sites progres-
sively increased comparing hearts with concentric compen-
satory hypertrophy (early stage of LV remodeling) (3 cases),
decompensated eccentric hypertrophy (hypertrophy and di-
lation, transition stage) (3 cases), and eventual ventricular
dilation with wall thinning (end stage) (7 cases) (Fig. 4).
DISCUSSION
This study not only confirms previous evidence of the
presence of myocardiocyte apoptosis late after AMI (9–
11,13–15) but also shows that apoptosis, both at the site of
infarction and in unaffected sites of the LV, correlates with
unfavorable post-infarction LV remodeling and the occur-
rence of HF after AMI. In fact, patients with enhanced
myocardial apoptosis at the site of infarction at the time of
death were significantly more likely to have hearts with signs
of unfavorable remodeling and to have suffered from symp-
toms or signs of HF early after AMI.
Saraste et al. (21) have shown that patients with more
severe HF and rapid clinical progression had higher AR at
the time of transplantation versus patients with slower
progression. This correlation between AR and disease
progression in dilated cardiomyopathy has been recently
prospectively validated in a study by Metzger et al. (22) in
patients undergoing partial ventriculectomy.
The association between apoptosis and unfavorable prog-
nosis may be, at least in part, explained by a causal role of
myocardiocyte apoptosis in the pathophysiology of progres-
sive cardiac remodeling leading to cardiac and circulatory
failure. Indeed, there is in our data a statistically relevant
correlation between AR and gross parameters of LV remod-
eling, as LV cavity size. The latter is considered a strong
independent clinical prognostic factor (23) and a potential
surrogate end point for prognosis in patients with HF (24).
Moreover, AR correlated not only with macroscopic signs
assessed at pathology but also with the signs and symptoms
of decompensated HF before death. Interestingly, the oc-
currence of these features does not appear irrelevant in the
clinical assessment of patients with HF, because it is
associated with increased mortality independently from
other clinical variables (such as LV ejection fraction) (25–
28). Although speculative, it is possible that enhanced
apoptosis may be responsible for a more rapid disease
progression in patients showing unfavorable cardiac remod-
eling and symptomatic HF. It has been suggested that the
peripheral circulation, more than cardiac performance, is
responsible for the development of symptoms (29). In fact,
it is difficult from morphologic examination of the heart to
differentiate a damaged but compensated heart from one
that is failing. This may suggest that peripheral neurohor-
monal rearrangements may be associated with more pro-
nounced clinical presentation and may be responsible, at
least in part, for progressive deterioration of HF (30).
Initial phases of cardiac remodeling are often character-
ized by compensatory cardiac and non-cardiac mechanisms.
Left ventricular hypertrophy of the surviving portions of the
heart is considered an initially effective compensatory phe-
nomenon (3), characterized by a low-grade apoptosis and a
more favorable prognosis when compared with LV dilation.
Figure 4. Myocardial apoptosis in progressive left ventricular (LV) remod-
eling. Increasing apoptotic rate (AR) in infarct (A) and remote sites (B) in
progressive unfavorable LV remodeling. Column height  median value;
vertical bar  interquartile range. p  0.050 at Kruskal-Wallis three-way
test for A, and p  0.11 for B. No statistically significant differences were
found comparing the three groups separately at Mann-Whitney, Bonfer-
roni adjusted, two-way U test. *p  0.014 for cases with compensatory
hypertrophy (AR of 3.2% [0.5 to 12.0]) versus the other two groups
characterized by LV dilation combined (AR of 26.0% [22.6 to 28.7]) (at
Mann-Whitney U test). **p  0.050 for cases with end-stage dilation (AR
of 0.9% [0.7 to 1.1]) versus the other two groups with LV hypertrophy
combined (AR of 0.4% [0.3 to 0.7]) (at Mann-Whitney U test).
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Apoptosis may play a role in the transition from compen-
sated concentric hypertrophy to decompensated eccentric
hypertrophy (31–33).
Increased plasma norepinephrine levels are part of the
peripheral neurohormonal rearrangements (30). Interest-
ingly, they are associated with a worse prognosis (34),
whereas treatment with beta-blockers favorably affects prog-
nosis in patients with HF (35). Of note, beta1-receptor
agonism is associated with myocardiocyte apoptosis in vitro
(36), and treatment with metoprolol significantly reduces
myocardiocyte apoptosis in an experimental HF model in
dogs (15). The same effects appears to be exerted by
angiotensin II (34,37), whereas angiotensin-converting en-
zyme inhibitors modulate the unfavorable neurohormonal
rearrangements (34), cardiac remodeling (38), and apoptosis
(14) and improve symptoms and prognosis in HF.
Therefore, two forms of apoptosis appear to affect the course
of post-infarction remodeling, both leading to unfavorable LV
remodeling and symptomatic HF: ischemia-driven apoptosis
at the site of recent infarction (7–10,13–15,21), and load-
dependent or receptor-dependent apoptosis at sites remote
from the ischemic area (11,32,33,36,37,39). An early article
by Gottlieb et al. (40), being the first study to evaluate
apoptosis in the ischemic heart, reported an increased AR in
an ischemia-reperfusion model, suggesting that apoptosis
was associated with reperfusion more than with hypoxia
alone and supporting the concept that completion of the
apoptotic cascade depends on the available energetic levels
(6). However, subsequent studies have completed this sce-
nario by showing that, although reperfusion after myocar-
dial ischemia accelerates apoptosis in the non-salvageable
myocardiocytes, reperfusion is also associated with a signif-
icantly lower total number of cells undergoing apoptosis,
supporting an overall beneficial effect by reperfusion (41).
Caspase-3 activation represents one of the terminal phases
of the apoptotic cascade, thus representing a potential target
for anti-apoptotic therapy. Although initial experimental
studies using caspase inhibitors in animal models showed
interesting results, clinical trials using such inhibitors are
still ongoing (42).
Most studies investigating apoptosis in vivo or ex vivo,
including the present study, however, suffer from the major
drawback of selection bias. Indeed, the evaluation of sub-
jects dying 10 to 62 days after AMI may have led to the
selection of a group of patients with more adverse prognosis
and extremely elevated AR, in comparison to the great
majority of cases surviving several weeks and months after
AMI. These considerations may explain the differences in
AR in our samples when compared with animal models or
with models of end-stage HF in patients undergoing cardiac
transplantation, even if both of these models may suffer
from inverse selection bias (6). As discussed by Sam et al.
(11), the evaluation in animal models of only those individ-
uals surviving until the established temporal end point for
sacrifice may have led to underestimation of AR, as nearly
65% of the animals died spontaneously beforehand and
therefore were not analyzed (11). Similarly, analysis of the
hearts explanted from patients undergoing cardiac trans-
plantation (12,21) may have not been able to assess AR in
those patients with more severe HF who did not survive
long enough to receive a cardiac transplant. In vivo valida-
tion of our data will therefore be necessary, and it would be
extremely useful also to assess whether patients with in-
creased myocardial apoptosis may be identified early
through determination of clinical characteristics (such as
signs of HF), of levels of plasma markers (such as soluble
tumor necrosis factor receptors [43]), and/or of apoptosis-
targeted molecular imaging such as myocardial perfusion
scan using marked annexin V (44).
Conclusions. Results in our data show that in patients
with AMI dying 10 to 62 days after the infarction with
persistent IRA occlusion at the time of death, apoptosis is
strongly associated with, and may be a major determinant
for developing, unfavorable LV remodeling and early symp-
tomatic HF. A direct cause–effect link, however, cannot be
assumed by our data, and further studies are required to
define the precise mechanisms and impact of apoptosis on
ischemic LV dysfunction, as well as potential applications in
the development of improved diagnostic and therapeutic
measures. Given the small sample size, the borderline
statistical significance in some of the analyses performed,
the possible confounding factors, and the unknown duration
of the apoptotic cascade in human myocardiocytes, mecha-
nistic and causal connections should be cautiously drawn.
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